KVUE — Kenvue Inc.
$19.57-1.56%
Last close: · regular session
Last 60 sessions
KVUE closed at $19.57 (-1.56%) on Oct 23, 2026. Float: 1.9B shares. Latest SEC filing: SCHEDULE 13G/A on Aug 6, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for KVUE in the TickerWise workspace.
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
Company profile
- Sector: Consumer Defensive
- Industry: Household & Personal Products
- Country: US
- Exchange: NYSE
- Employees: 22,000
- Website: https://www.kenvue.com
Latest SEC filings for KVUE
Latest KVUE news
- Kimberly-Clark's $40B purchase of Kenvue wins China antitrust approval Read article
- Kimberly-Clark wins EU conditional approval for $40B purchase of Kenvue Read article
- Kimberly-Clark, Kenvue Win Conditional EU Approval for $40 Billion Tie-Up Read article
- Kimberly-Clark Announces Successful Consent Solicitations for Kenvue Notes and Amendment to Terms of Exchange Offers Read article
- Market Concentration Is Spooking Wall Street—I'm Buying Kenvue Read article
- NWL or KVUE: Which Is the Better Value Stock Right Now? Read article
- Kimberly-Clark Pays Out Almost Everything It Earns. Can the Dividend Survive the Kenvue Deal? Read article
- Kimberly-Clark Corporation Announces Commencement of Exchange Offers and Consent Solicitations for Kenvue Notes Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.